Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Technical Performance Evaluation of Olink Proximity Extension Assay for Blood-Based Biomarker Discovery in Longitudinal Studies of Alzheimer's Disease

6 Jun 2022

Abstract excerpt

The core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers; amyloid-β (Aß), total tau (t-tau), and phosphorylated tau (p-tau181), are strong indicators of the presence of AD pathology, but do not correlate well with disease progression, and can be difficult to implement in longitudinal studies where repeat biofluid sampling is required. As a result, blood-based biomarkers are increasingly being sought...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Proteomics Techniques and Applications
Share to Alzheimer's disease research and treatments
Share to Metabolomics and Mass Spectrometry Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35734478
DOI: 10.3389/fneur.2022.889647

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Technical Performance Evaluation of Olink Proximity Extension Assay for Blood-Based Biomarker Discovery in Longitudinal Studies of Alzheimer's DiseasePMID 35734478Read ↗

Proximity extension assay‐based proteomics studies in neurodegenerative disorders and multiple sclerosisSemantic proximity Read ↗

Head-to-head comparison of aptamer- and antibody-based proteomic platforms in human cerebrospinal fluid samples from a real-world memory clinic cohortSemantic proximity Read ↗

Analytical and Clinical Validation of a High Accuracy Fully Automated Digital Immunoassay for Plasma Phospho-Tau 217 for Clinical Use in Detecting Amyloid PathologySemantic proximity Read ↗

Validation and pre-analytical considerations for processing cerebrospinal fluid samples on a high-throughput proximity extension assay platformSemantic proximity Read ↗

Blood biomarkers for Alzheimer’s disease with the Lumipulse automated platform: Age-effect and clinical value interpretationSemantic proximity Read ↗

Plasma biomarker profiles in autosomal dominant Alzheimer’s diseaseSemantic proximity Read ↗

Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsSemantic proximity Read ↗

Multi-Platform Comparison of Plasma Phosphorylated Tau Assays: Analytical and Workflow Factors Drive Clinical Implementation DecisionsSemantic proximity Read ↗

An automated plasma-based proteotyping immunoassay for APOE ε4 zygosity classification in Alzheimer's disease.Semantic proximity Read ↗

Circulating biomarkers of protein oxidation for Alzheimer disease: Expectations within limitsSemantic proximity Read ↗

Tau pathological binding activity in plasma before the onset of symptomatic Alzheimer’s diseaseSemantic proximity Read ↗

Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72 -associated frontotemporal dementia and amyotrophic lateral sclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.